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Abstract:  
Mantle cell lymphoma (MCL) and the marginal zone lymphoma (MZL) subtypes 
(nodal MZL, extra-nodal MZL of mucosa-associated lymphoid tissue (MALT 
lymphoma) and splenic MZL) are uncommon lymphoma subtypes, accounting for 
less than 5-10% of all non-Hodgkin lymphoma. The evidence base for therapy is 
therefore limited and enrolment into clinical trials is preferred. Outcomes for patients 
with MCL have been steadily improving mainly due to the adoption of more intense 
strategies in younger patients, the use of rituximab maintenance and the recent 
introduction of bendamustine in older patients. MZLs are more heterogenous group of 
cancers with both nodal, extra-nodal and splenic subtypes. Extranodal MZL may be 
associated with autoimmune or infectious aetiologies, and can respond to eradication 
of the causative pathogen. Proton pump inhibitor plus dual antibiotics in H Pylori 
positive gastric MALT lymphoma is curative in many patients. Watchful waiting is 
appropriate in most patients with asymptomatic advanced stage disease, which tends 
to behave in a particularly indolent manner. Other options for symptomatic disease 
include splenectomy, chemoimmunotherapy with rituximab and, more recently, 
targeted therapies.  
 
Keywords: mantle-cell lymphoma, marginal zone B-cell lymphoma, disease 
management, rituximab, bendamustine   
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Introduction 
Part 1 of this two-part series on indolent non-Hodgkin lymphoma (NHL) discussed 
the front-line management of follicular lymphoma, the second most common subtype 
of NHL. In this second article, we discuss the less frequently encountered subtypes 
mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL). Waldenstrӧ m’s 
macroglobulinemia was the subject of recently published comprehensive guidelines.1 
The Australian Institute of Health and Welfare reports an age-standardised incidence 
rate for NHL of 19.4 per 100 000 person–years for 2013; data for subtypes are not 
reported separately.2 Older Australian incidence data, from 1997–2006, have been 
published for MCL and MZL, showing annual age-standardised rates of 0.5 per 
100 000 person–years for both.3 
 
Mantle cell lymphoma 
MCL accounts for about 5% of all NHL and is approximately three times more 
common in men than in women.4 The majority present at an advanced stage with a 
median age at diagnosis of 68 years.5, 6 Although most cases are clinically aggressive, 
up to one third of patients have an indolent presentation where initial therapy can be 
deferred until progression.5, 7 These cases are characterised by non-nodal presentation 
(leukaemic disease and splenomegaly) and feature IgVH hypermutation and genetic 
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stability. CD200, positive in only 4% of MCL cases overall, may be a potential 
marker for these cases.8  
Diagnosis and Staging 
Around three-quarters of patients with MCL present with generalised 
lymphadenopathy and extra-nodal involvement in bone marrow, gastrointestinal tract 
and peripheral blood is frequent.6 Excisional lymph node biopsy is preferred over core 
biopsy to secure diagnosis.9 Most cases display a monomorphic neoplastic lymphoid 
infiltrate with a variety of histologic patterns including nodular, diffuse, pleomorphic 
and blastoid, the latter two being more clinically aggressive.10 By 
immunophenotyping, typically CD19, CD20, CD22 CD43, CD79a, CD5 and FMC7 
are positive, while CD23, CD10, CD200 and BCL6 are negative.10 MCL is 
characterised by t(11;14)(q13;q32) translocation resulting in cyclin D1 overexpression 
and demonstration of t(11;14)(q13;q32) by FISH or cyclin D1 by 
immunohistochemistry is required to secure the diagnosis. Rare cases of cyclin D1 
negative MCL have been reported, however, and SOX11 expression and 
rearrangements of CCND2 may then be of diagnostic utility.9-11 Ki-67 e  30% is 
adversely prognostic for survival, independent of histology and growth pattern.4, 12 
Staging is carried out using the Lugano classification (Table 1),9 and 
recommended procedures include physical examination, peripheral blood examination 
including morphologic assessment and flow cytometry to detect leukaemic disease, 
computed tomography (CT) scan, and bone marrow aspirate and biopsy. Positron 
emission tomography (PET) is not mandatory, but useful to confirm stage I/II 
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disease.6 Endoscopy and blind biopsy can reveal gastrointestinal involvement in up to 
95% of cases;4 however, this rarely changes management and should be reserved for 
patients with apparent stage I/II disease or gastrointestinal symptoms. The combined 
MCL International Prognostic Index (MIPI-c), integrating the MIPI (age, performance 
status, lactate dehydrogenase level, white blood cell count) and MIPI biologic (MIPI-
b, comprising MIPI and the Ki-67 index), is useful for prognostication (Table 2).12 
Current treatment approaches 
There is no international consensus regarding the optimal induction therapy for 
patients with MCL. Although MCL is typically initially chemosensitive, most patients 
eventually experience relapse.5 
Stages I-II 
MCL presenting with truly limited stage disease is rare (<5% of all patients) and has 
more favourable outcomes.5 The largest study included 179 patients (75% head and 
neck) who received either chemotherapy, chemo-radiation or radiation alone.13 The 
10-year overall survival (OS) rates were similar at 69%, 62% and 74%, respectively 
and 10-year freedom from progression rates were also similar at 46%, 43% and 31%. 
While radiation monotherapy results in long term disease control in only around one-
third of patients, it is a reasonable option for elderly or frail patients. The optimal 
treatment approach is therefore unclear, with decisions influenced by patient age and 
fitness, expected toxicity, disease bulk and number of nodal sites. 
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Stages III and IV 
Patient age and comorbidities determine the therapeutic approach in stage III–IV 
disease and enrolment into clinical trials subject to availability and eligibility is 
preferred. A suggested approach for advanced stage MCL in the Australian healthcare 
setting is outlined in Figure 1. The intent of treatment is to alleviate symptoms, 
induce remission and prolong life. The incorporation of high-dose cytarabine, 
autologous stem cell transplant (ASCT) and rituximab maintenance have all resulted 
in incremental improvements in survival in the frontline setting.6  
Patients with asymptomatic disease can be safely observed, without 
compromising OS, from time of treatment initiation.14 Observation is appropriate for 
patients with Ki-67<30%, non-blastoid/pleomorphic histology, maximum tumour 
diameter < 3cm, normal LDH/² 2-microglobulin and no B symptoms or cytopenias.
6 
First line treatment: Fit for intensive therapy 
For fit patients, usually <65 years, regimens containing high-dose cytarabine ± ASCT 
have achieved the best results.15-18 
In the EMCLN “Younger” study, Hermine et al. randomised 497 patients under 
65 years with treatment-naïve MCL to six cycles of either R-CHOP (rituximab, 
cyclophosphamide, doxorubicin, vincristine and prednisone) or R-CHOP alternating 
with DHAP (dexamethasone, cytarabine and cisplatin), followed by ASCT.16 After a 
median follow-up of 6.1 years, the time to treatment failure was longer in the R-
CHOP/DHAP group (median 9.1 vs 3.9 years; HR, 0.56 [P=0.038]) with increased 
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grade e3 haematologic toxicity and febrile neutropenia. There was no difference in 
OS.  
Le Gouill et al. performed a phase III study in which 299 patients aged <66 
were treated with 4 cycles of R-DHAP (CHOP reserved for patients not in complete 
remission (CR)) and ASCT then randomised to either rituximab maintenance (every 2 
months for 3 years) or observation.17 Few patients actually required the anthracycline 
after DHAP; 257 patients received ASCT and 240 patients were randomised to either 
maintenance rituximab or observation. Patients who received rituximab maintenance 
had superior 4 year rates of event-free survival (EFS 79% vs 61%, P=0.001) and OS 
(89% v 80%, P=0.04). 
Other effective induction regimens shown in phase II studies to result in durable 
remissions are rituximab with alternating cycles of maxi-CHOP and high-dose 
cytarabine (Nordic MCL2),15 and rituximab with alternating cycles of fractionated 
cyclophosphamide, vincristine, doxorubicin and dexamethasone (hyper-CVAD) and 
high-dose methotrexate and cytarabine (MA).18, 19  
ASCT following high-dose induction has been included in most phase II and III 
studies in transplant eligible MCL patients,16, 17, 20 following demonstration of its 
superiority over interferon maintenance in a randomized trial.21 The EBMT/EMCLN 
consensus statement recommends consideration of ASCT as the first consolidation 
strategy in patients fit for high-dose therapy,22 as do the recent ESMO guidelines.4 
While limited available evidence suggests consolidation with allogeneic SCT 
provides progression free survival (PFS)/OS similar to ASCT we do not advocate its 
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use outside clinical trials due to the greater risk of transplant-related mortality and 
graft-versus-host disease.23-26 High-dose chemotherapy with autologous stem cell 
transplant in fit patients is generally best performed as initial therapy rather than in 
relapsed or refractory disease.4 
Even with intensive therapy there appears to be a continuous pattern of relapse 
without a plateau in survival as evidenced by the 15-year follow up of the Nordic 
MCL2 and MD Anderson R-HCVAD/MA phase II trials.19, 27 
First line treatment: Fit for conventional dose therapy   
In older patients suitable for conventional dose chemoimmunotherapy, choices 
include bendamustine-rituximab (BR) and R-CHOP. The randomised Stil-NHL28 and 
BRIGHT29 studies, which included patients with MCL, suggested a PFS advantage 
for BR (over R-CHOP and R-CHOP/rituximab, cyclophosphamide, vincristine, 
prednisone (R-CVP), respectively) in the absence of rituximab maintenance, although 
the former study was a non-inferiority design. R-CHOP followed by rituximab 
maintenance was established as a reasonable standard of care in the EMCLN Elderly 
study.30 Rituximab maintenance is currently not reimbursed by the Pharmaceutical 
Benefits Scheme (PBS) in Australia for MCL. Thus, given the relatively favourable 
toxicity profile, BR is a reasonable initial therapy in fit, transplant-ineligible patients. 
No survival advantage has been shown for rituximab maintenance after BR initial 
therapy in older patients with MCL.31   
The addition of intermediate dose cytarabine (500mg/m2) to BR (bendamustine 
70mg/m2) resulted in encouraging efficacy in a small phase II study of patients over 
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60 yrs who were unfit for transplant. Forty two out of 57 patients (76%) were free 
from progression after a median follow-up of 35 months.32 The addition of cytarabine 
to bendamustine increases haematologic toxicity and whether it improves outcomes is 
not yet definitively proven; as such, this regimen should only be considered for those 
with low rates of comorbidity and adequate organ function.  
Cytarabine-based chemoimmunotherapy (R-hyperCVAD/R-MA; R-CHOP/R-
DHAC) significantly improved OS and PFS over a median follow-up of 40 months 
without ASCT in patients > 60 years (median age 69 years).33 The use of this 
treatment in older patients is based on extension of the experience in younger patients 
where incorporation of cytarabine significantly improves outcomes, however the 
toxicity is an important consideration. Of note, the Nordic MCL5 trial examining the 
combination of cytarabine and rituximab was abandoned early after poor outcomes 
were noted in four of the first five patients enrolled.34 
Unfit for conventional dose therapy  
Frail elderly patients may be offered reduced dose BR (50-70mg/m2) or R-CVP with 
consideration given to abbreviating therapy to 4 cycles if significant toxicities occur. 
In contrast to follicular lymphoma, rituximab monotherapy and radioimmunotherapy 
have limited efficacy and should be avoided.4 
Relapsed disease:  
There is no standard therapy for patients with relapsed/refractory MCL and enrolment 
to clinical trials should be prioritised. Young/fit patients with chemosensitive disease 
may be considered for potentially curative allogeneic SCT.35 Salvage therapy with 
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non-cross resistant chemotherapy (e.g. DHAP following CHOP or vice versa) in 
relapse under 12 to 24 months can produce high overall response rate (ORR) but 
disease control is brief (median PFS <2 years).6 Bendamustine with rituximab has 
high ORR and durable disease control36 but is currently not PBS-reimbursed in the 
relapsed/refractory setting in Australia. 
Non-chemotherapy options in patients with early relapse, chemo-refractoriness 
and not transplant-eligible include Bruton’s tyrosine kinase (BTK) inhibitors (such as 
ibrutinib and other second generation agents), lenalidomide, temsirolimus and 
bortezomib. Of these, only ibrutinib is reimbursed by the PBS for use in relapsed/ 
refractory MCL. Pooled analysis of the SPARK, RAY and PCYC-1104 studies of 
treatment with ibrutinib in early relapsed/refractory MCL showed 26.5% of patients 
achieved a CR over median follow-up of 3.5 years, 26% were progression free at 3 
years, and 45% were alive at 3 years (median PFS, 13 months; median OS, 26.7 
months).37 The results of the combination of ibrutinib and venetoclax in a small phase 
2 study appear to indicate synergistic activity with a 71% PET-CT CR rate at 16 
weeks and high rates of MRD negativity,38 and have led to an ongoing global phase 
III randomised study comparing ibrutinib/venetoclax to ibrutinib/placebo 
(SYMPATICO; NCT03112174). 
 
Marginal zone lymphoma 
Collectively, MZL is the third most common B-cell lymphoma and the second most 
common indolent lymphoma (5%-17% of all NHL).39, 40 Three distinct subtypes are 
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recognized. Extra-nodal MZL of mucosa-associated lymphoid tissue (MALT 
lymphoma) accounts for 50 – 70% of cases, while nodal MZL represents around 10%, 
and splenic MZL approximately 20% of MZL cases.10, 41 
MALT lymphoma 
MALT lymphoma can arise in virtually all tissues where chronic antigenic stimulation 
by infectious pathogens or autoimmunity can induce inflammatory lymphoid 
populations.41 The stomach is the most frequent site with gastric MALT accounting 
for at least one third of patients.42 Other common sites include the ocular adnexa, 
salivary gland, skin, conjunctiva, lung, thyroid and breast, with potentially diverse 
site-specific aetiologies (Table 3).40 The strongest evidence for a specific aetiologic 
pathogen relates to Helicobacter Pylori-induced chronic gastritis implicated in around 
two thirds of gastric MALT cases. Autoimmune diseases such as Sjogren’s syndrome 
and Hashimoto’s thyroiditis are associated with increased risk of MALT lymphoma of 
the salivary gland and thyroid respectively. Clinical presentation of MALT lymphoma 
varies widely according to the site(s) of involvement. Typically, they are biologically 
indolent and patient outcomes are generally favourable.39 
Diagnosis and staging 
MALT lymphomas characteristically remain localized for prolonged periods although 
multi-focal single organ involvement and systemic dissemination can occur in up to 
25% of cases (more likely with non-gastric sites).41, 43 Patients with bone marrow 
involvement (approximately 20%) or nodal dissemination have a worse prognosis41 
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and require different therapeutic strategies from patients with localised disease.42 
Thus careful staging is required and the diagnostic work up should be tailored 
according to the site involved and any possible underlying infectious or autoimmune 
causes.41 Endoscopic ultrasound is recommended for staging of gastric MALT. The 
MALT international prognostic index (MALT-IPI) is useful for prognostication.44 
Current treatment approaches 
Gastric MALT lymphoma 
In patients positive for H pylori infection, standard eradication therapy with a proton 
pump inhibitor plus dual antibiotics should be instituted. H pylori eradication alone is 
reported to result in localized gastric MALT lymphoma regression in 75% of cases.41 
Re-testing at two months with a breath test, following cessation of proton pump 
inhibitors for at least one month, should be undertaken to ensure eradication before re-
assessing the lymphoma status endoscopically three months after eradication.42, 45 
For patients with localized disease who are H pylori negative, empiric eradication 
therapy may still be beneficial in a significant proportion of patients.46 Similarly, 
clarithromycin therapy has resulted in meaningful response rates in some patients 
with gastric MALT lymphoma (and other subtypes).47 
For patients who have failed eradication therapy, there is no clear consensus on 
the best treatment approach. Involved site radiotherapy is favoured by many, with 
excellent reported outcomes using moderate doses (24–30 Gy over 3–4 weeks).45 One 
study which included patients with localized gastric or non-gastric MALT lymphoma 
reported 10-year overall and recurrence-free survival rates of 87% and 76% 
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respectively, with cause-specific survival of 98%.48 Other treatment options include 
chemoimmunotherapy, most commonly R-chlorambucil49 and R-CVP42. Gastrectomy 
has been used historically and although potentially curative, is often associated with 
significant long-term morbidity and is rarely considered in current practice. 
Non-gastric MALT lymphoma 
Patients with localized disease in other sites associated with a postulated causative 
pathogen (Table 3) should be considered for eradication therapy, although the 
aetiologic relationship and outcomes following eradication are less well established. 
Response rates of around 50% have been reported for ocular adnexal MALT 
associated with C psittaci in patients treated with prolonged doxycycline or 
clarithromycin50 However, the specificity of PCR testing in this setting is unknown 
and disease regression using antibiotics has been reported in 6 of 16 C psittaci – 
negative cases.51 Thus testing and an empiric trial of eradication is a reasonable 
approach. Data regarding response rates to antibiotics in the other subtypes are scant 
and no firm conclusions can be drawn. Local radiotherapy is often the treatment of 
choice for localized non-gastric MALT lymphoma.52  
Advanced stage disease 
Advanced stage MZL of MALT type is incurable and the usually indolent biology 
allows for a watch and wait approach in most patients. When treatment is required, 
systemic chemoimmunotherapy has been used successfully. The addition of rituximab 
to chlorambucil improved outcomes compared to either agent alone.49 Bendamustine 
plus rituximab has been reported as safe and effective in a phase 2, trial of 60 patients 
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with a median follow-up of 43 months.53 Event-free survival was 93% (95% CI, 84-
97%) at two years and 88% at 4 years.  
Many trials of other agents effective in B-cell lymphomas have included a few 
patients with MALT lymphoma; however, the numbers are insufficient to draw 
conclusions and all such agents remain investigational. Lenalidomide and bortezomib 
have shown activity in phase 2 studies.54, 55 Ongoing trials recruiting patients with 
MZL of MALT type should always be considered for patients with this uncommon 
disease. 
Nodal MZL 
Nodal MZL is the least common of all the MZLs representing approximately 10% of 
MZLs and <2% of all NHL.40, 56 The median age at presentation is 60 years with both 
genders equally affected.57 The understanding of nodal MZL has been hampered by 
its rarity, with therapeutic strategies largely based on data from follicular or small 
lymphocytic lymphoma. In common with these disorders, the disease generally 
behaves in an indolent fashion and is often disseminated at presentation. Histologic 
transformation is reported in 3-15% of patients with nodal MZL and is often 
associated with a poor outcome.58 In a large retrospective series, the crude incidence 
of histologic transformation was 34/453 (7.5%) with elevated serum lactate 
dehydrogenase (LDH), >4 nodal sites and failure to achieve CR associated with 
increased risk of transformation by multivariable competing risk regression analysis.59 
While there is an association with hepatitis C infection (Table 3),60 a history of 
autoimmunity is less common than with other forms of MZL.61 
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Like other indolent NHL, nodal MZL is largely incurable with a course 
characterised by periods of remission and relapse. The largest dataset informing 
prognosis of patients with nodal MZL is the US SEER dataset from 4724 patients.57 
While the 10-year overall survival of patients with nodal MZL is only 44.3%, nearly 
half the recorded deaths are unrelated to lymphoma, being mainly cardiovascular 
disease and other malignancies.62 A reduction in lymphoma related death in cases 
diagnosed after 2000 was also noted possibly due to the introduction of rituximab.62, 63  
Diagnosis and Staging 
Peripheral lymphadenopathy involving the head and neck lymph nodes is common at 
presentation, with up to one third of patients having bulky tumours (>5 cm) and about 
half having stage III/IV disease (Table 1).61 Approximately 10% of patients will 
present with an IgM paraprotein,56 which can result in the diagnosis being confused 
with Waldenstr ӧm’s macroglobulinaemia. The absence of MYD88 L265P mutation (a 
feature of Waldenstr ӧm’s macroglobulinemia       
although it may also be observed in roughly 15% of SMZL.64  
Nodal MZL demonstrates similar cytologic, immunophenotypic and genetic 
features to both splenic and extranodal MZL which may result in diagnostic difficulty, 
particularly in cases with involvement of spleen or extranodal sites.56 
Validated prognostic scoring systems are lacking in nodal MZL, with conflicting data 
regarding the applicability of FLIPI.63, 65 Increased age and advanced stage have 
however been associated with adverse prognostic impact.62 
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Current treatment approaches 
The standard therapy for nodal MZL is yet to be defined with many centres 
employing strategies used in follicular lymphoma. Patients with localised disease 
respond well to radiotherapy, and those with minimally symptomatic, low tumour 
burden, advanced stage disease are suitable for watchful waiting.56 Reports of 
regression of MZL with eradication of hepatitis C infection support this strategy as an 
initial approach in hepatitis C infected patients.66, 67 Patients with disseminated 
disease and high tumour burden can be treated with chemoimmunotherapy.57 
Chemoimmunotherapy 
Despite the lack of prospective data, chemoimmunotherapy with rituximab is 
generally considered standard treatment for patients with symptomatic advanced stage 
disease. As patients may require treatment over an extended period, consideration 
should be given to limiting prolonged or repeated exposure to alkylating agents and 
purine analogues to minimize the risk of myelodysplasia and the impact on the ability 
to harvest stem cells for transplant. 
Various first line chemoimmunotherapy regimens have been examined 
including R-CVP,68 R-CHOP,28 fludarabine and rituximab (FR),69 fludarabine, 
cyclophosphamide and rituximab (FCR)70 and BR28, 71 (Table 4). R-CHOP and BR 
were associated with similar progression free survival (47.2 months and 57.2 months 
respectively, p=0.3249) in various MZL subtypes, including nodal MZL.28 While data 
on BR and R-CHOP in nodal MZL are limited, the available studies confirm the high 
tolerability, response rates and durability of these combinations. The toxicity and poor 
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tolerability of fludarabine-based regimens particularly in older patients, have rendered 
them largely of historic interest. 
There is limited data on the role of autologous stem cell transplantation as front 
line therapy in NMZL; however, it may be a useful strategy in selected patients with 
chemo-sensitive disease in the relapsed setting.72 
Genetic studies of NMZL have identified actionable mutations involving B-cell 
receptor, JAK/STAT, NF-º B, NOTCH, and Toll-like receptor signalling pathways.73 
Several agents targeting these (bortezomib, everolimus, idelalisib, copanlisib, 
ibrutinib, zanubrutinib) are currently under investigation, mainly in patients with 
relapsed and refractory disease. 
Splenic MZL 
Splenic MZL (SMZL) makes up less than 2% of all lymphoid malignancies, and 20% 
of all MZL. It is usually indolent, with a median survival of 8–10 years, but can 
transform to diffuse large B-cell lymphoma in ~5–10%.74, 40 Approximately one third 
of patients have no symptoms, and a watch and wait approach has no adverse impact 
on overall survival.75 
Diagnosis & staging 
Distinguishing SMZL (also referred to as splenic lymphoma with villous 
lymphocytes) from other indolent B-cell lymphoproliferative disorders is challenging, 
with a definitive diagnosis relying on spleen histology.74 However, in most patients 
the diagnosis can be suggested by the characteristic morphology of circulating 
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lymphoma cells with polar villous cytoplasmic projections and round nucleus (in 
contrast to the larger hairy cell leukaemia (HCL) cells with evenly spaced 
circumferential cytoplasmic projections and an oval or bean shaped nucleus).10  
Immunophenotyping of circulating or bone marrow lymphocytes demonstrates 
IgM +/- IgD, CD19, CD20, CD22 and BCL-2 expression. Lack of CD5 (usually), 
CD23, CD25, and CD103 along with Cyclin D1 negativity assist in excluding chronic 
lymphocytic leukaemia (CLL), mantle cell and, importantly, HCL which also causes 
prominent splenomegaly. In common with nodal MZL an IgM paraprotein may occur 
and MYD88 mutation testing can help distinguish from Waldenstr ӧm 
macroglobulinaemia.76 A small fraction of patients harbour hepatitis C infection 
(Table 3), which should be treated as tumour responses are frequent.66  
Splenic hilar lymphadenopathy occurs in 25% of SMZL but peripheral 
lymphadenopathy is uncommon.77, 78  
While most patients present with splenomegaly and lymphocytosis (often noted 
incidentally), cytopenias, most commonly due to hypersplenism, is found in ~25%.77 
Autoimmune haemolytic anaemia and other autoimmune phenomena can occur. 
SMZL staging is completed with CT. PET is seldom contributory unless 
transformation is suspected.74 
Current treatment approaches 
A watch and wait approach is used with follow-up every 3-6 months, and treatment 
recommended only in the presence of symptomatic splenomegaly, cytopenia, 
systemic symptoms or progressive nodal disease.74, 75 Treatment options in SMZL 
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include splenectomy, rituximab monotherapy, chemotherapy, chemoimmunotherapy 
(with rituximab) for disseminated disease and high-grade transformation, and new 
targeted therapies.74 
Splenectomy 
Splenectomy was the mainstay of therapy for decades before rituximab monotherapy 
became the popular choice for this patient population, which is mostly elderly with 
comorbidities. Nonetheless, splenectomy removes a significant burden of disease, 
ameliorating abdominal discomfort and resolving cytopenias due to splenic 
sequestration, as opposed to those due, less commonly, to extensive marrow 
involvement.74 After surgery, patients can remain free from treatment for many years. 
One additional advantage of splenectomy is that a definitive diagnosis of SMZL can 
be established.74 Short-term perioperative complications of splenectomy can be 
reduced with the laparascopic approach and prophylaxis against venous 
thromboembolism. The long-term risk of infections, specifically with encapsulated 
bacteria, can be minimised with vaccinations at least two weeks before elective 
splenectomy.74 Oral amoxicillin use in accordance with the Spleen Australia infection 
prophylaxis guidelines, accessible at https://spleen.org.au/VSR/information.html, 
should be followed.79 
Chemoimmunotherapy 
Combination rituximab chemotherapy is appropriate for fit patients with disseminated 
disease, constitutional symptoms, and/or signs of high-grade transformation.74 It is 
recognised that R-CVP and R-CHOP, both commonly used in follicular lymphoma, 
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may be treatment options in Australia for SMZL; however, the largest body of data is 
for R-COMP (rituximab with cyclophosphamide, vincristine, non-pegylated 
liposomal doxorubicin (Myocet™) and prednisone) used in the prospective FIL 
trial.74 Fifty one patients achieved an ORR of 84%, 6-year PFS of 54% and OS of 
72%, although there was 26% grade>3 neutropenia and 8% grade>3 infections.74 The 
combination of rituximab with bendamustine has never been studied in a dedicated 
trial of SMZL but there were sufficient numbers of patients with MZL overall in both 
the BRIGHT29 and STiL28 studies to identify excellent response rates and possibly 
comparable PFS rates with BR, as with R-CVP and R-CHOP. The use of rituximab 
maintenance for 2 years following initial treatment with BR in both nodal and SMZL 
has been shown to significantly increase PFS (but not OS) compared to no 
maintenance (HR 0.35, 95% CI 0.17-0.76, p=0.008) in the STiL NHL7-2008 
MAINTAIN trial.80 
Rituximab monotherapy has been associated with ORRs of 90-100% in several 
retrospective studies, with approximately half the patients obtaining a CR 
(normalisation of both blood counts and splenomegaly);75 however, it is not currently 
reimbursed as monotherapy for splenic MZL in Australia or New Zealand.   
 
Summary 
Less frequently encountered subtypes of NHL, which include MCL and the three 
MZL subtypes (MALT lymphoma, nodal MZL and SMZL), are distinct clinico-
pathologic entities and require specific diagnostic and therapeutic considerations. 
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Most patients with MCL have advanced stage disease at diagnosis, with age and 
fitness of the patient influencing treatment approach. High dose cytarabine-containing 
chemoimmunotherapy and ASCT result in high response rates and durable remissions 
(median PFS 5-7 years) in younger/fitter patients, while older patients may be offered 
less intensive regimens such as BR. 
MZLs share a number of overlapping pathologic features with other indolent B-
cell lymphomas and present diagnostic challenges. Infectious and autoimmune 
aetiologies should be considered and, critically, gastric MALT subtype lymphoma is 
often associated with H Pylori infection – in which case eradication therapy is 
frequently successful. Nodal MZL and splenic MZL are both associated with hepatitis 
C in a minority of cases.  
Other entity-specific considerations include the role of splenectomy in SMZL. 
Systemic treatments for MZLs share similarities and depend on whether disease is 
localized or advanced, symptomatic or not, and patient age and fitness. Specific 
evidence for each entity is limited as patients are often included with follicular 
lymphoma in prospective studies. For localized disease, radiation therapy is 
frequently used. Recognizing the indolent biology, a watch and wait approach is 
usually appropriate in asymptomatic advanced stage patients. When treatment is 
indicated, common approaches include rituximab monotherapy where applicable and 
available, and chemoimmunotherapy with BR or R-CVP/R-CHOP regimens. Well-
designed clinical trials evaluating novel approaches in these specific entities are 
needed. 
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Figure 1: A suggested approach for treating advanced stage MCL in the 
Australian healthcare setting 
 
†Bendamustine 50-70 mg/m2 
R-DHAP: rituximab,  dexamethasone, high dose cytarabine plus cisplatin (could be 
substituted, if required, with the less nephrotoxic carboplatin or oxaliplatin); R-
CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine plus prednisone; R-
maxi-CHOP/HDAC: alternating cycles of R-CHOP and high-dose cytarabine; R-
HyperCVAD/MA: rituximab with alternating cycles of fractionated 
cyclophosphamide, vincristine, doxorubicin plus dexamethasone, and high-dose 
methotrexate plus high-dose cytarabine; R-BAC50: rituximab, bendamustine plus 
intermediate-dose cytarabine (500 mg/m2) 
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Table 1: Revised staging system for primary nodal lymphomas9 
Stage Involvement† Extranodal (E) Status 
Limited   
I Single node; OR 
group of adjacent nodes 
Single extranodal lesions 
without nodal 
involvement 
II e  2 nodal groups on same 
side of diaphragm 
Stage I or II by nodal 
extent with limited 
contiguous extranodal 
involvement 
II bulky‡ II as above with ‘bulky’ 
disease 
Not applicable 
Advanced   
III Nodes on both sides of 
the diaphragm; OR 
Nodes above the 
diaphragm with spleen 
involvement 
Not applicable 
IV Additional non-
contiguous 
extralymphatic 
involvement 
Not applicable 
†Extent of disease is determined by PET-CT for avid lymphomas and CT for non-avid 
histology. Nodal tissue includes tonsils, Waldeyer’s ring and spleen. 
‡Whether stage II bulky disease is treated as limited or advanced depends on histology 
and prognostic factors. 
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Table 2: Combined MIPI (MIPI-c)-defined prognostic groups 
MIPI Risk Group† Ki-67 index MIPI-c score‡ 5 -year OS 
Low (0) 
<30% (0) 0 85% 
e30% (1) 
1 72% 
Intermediate (1) 
<30% (0) 
e30% (1) 
2 43% 
High (2) 
<30% (0) 
e30% (1) 3 17% 
†The MIPI risk group is calculated using the following formula: [0.03535 × age (years)] + 
0.6978 (if ECOG > 1) + [1.367 × log 10(LDH/ULN)] + [0.9393 × log 10(white cells x 
109/L)].  A raw score < 5.7 indicates low-risk disease (MIPI-c score = 0–1); 5.7 to 6.2 
indicates intermediate risk (MIPI-c score = 1–2), and e  6.2 high risk (MIPI-c score = 2-3) 
‡MIPI-c is derived from a combination of the MIPI risk group score (0–2) and Ki-67 index 
score (0 if Ki-67<30; 1 if Ki-67 e30). 
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Table 3: Pathogens implicated in MZL lymphoma  
Pathogen Type of MZL lymphoma 
Helicobacter Pylori Gastric MALT 41 
Chlamydophila psittaci ocular adnexal MALT 41 
Campylobacter jejuni small intestinal MALT 41 
Borrelia burgdorferi cutaneous MALT 41 
Hepatitis C virus Nodal & splenic MZL 60 
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Table 4: Chemoimmunotherapy regimens in Nodal MZL  
Treatment Median duration 
of follow-up 
Progression-free survival Overall survival Study 
R-CVP 3-weekly for 
six or eight cycles 
(N=40) 
38.2 months At 3 years: 59% At 3 years: 95% Kang HJ et al.68  
2012 
R-CHOP 3-weekly for 
up to six cycles 
(N=253) versus BR 4-
weekly for up to six 
cycles (N=261) 
45 months R-CHOP: 31.2 months median 
(15.2-65.7) 
BR: 69.5 months median (26.1-
to not reached) 
HR, 0.58; 95% CI 0.44-0.74; 
p<0.0001 
Not assessed Rummel MJ et al.28 
2013 
FR 4-weekly for up to 
six cycles (N=26; only 
58% completed) 
3.1 years (1.0 – 
4.7) 
79.5% (95% CI, 63.4-95.6%)  87.4% (95% CI, 74-
99%) 
Brown JR et al.69 
2009 
FCR 4-weekly for up 40.9 months 90.1% (95% CI, 75.5-96.2%) 97.4% (95% CI, 83.2- Ferrario A et al.70 
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to 6 cycles (N=46; 
87.2% completed) 
99.6%) 2012 
 
R-CVP, rituximab, cyclophosphamide, vincristine plus prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine plus 
prednisone; BR, bendamustine plus rituximab; FR, fludarabine plus rituximab; FCR, fludarabine, cyclophosphamide plus rituximab 
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Abstract:  
Mantle cell lymphoma (MCL) and the marginal zone lymphoma (MZL) subtypes (nodal 
MZL, extra-nodal MZL of mucosa-associated lymphoid tissue (MALT lymphoma) and 
splenic MZL) are uncommon lymphoma subtypes, accounting for less than 5-10% of all non-
Hodgkin lymphoma. The evidence base for therapy is therefore limited and enrolment into 
clinical trials is preferred. Outcomes for patients with MCL have been steadily improving 
mainly due to the adoption of more intense strategies in younger patients, the use of 
rituximab maintenance and the recent introduction of bendamustine in older patients. MZLs 
are more heterogenous group of cancers with both nodal, extra-nodal and splenic subtypes. 
Extranodal MZL may be associated with autoimmune or infectious aetiologies, and can 
respond to eradication of the causative pathogen. Proton pump inhibitor plus dual antibiotics 
in H Pylori positive gastric MALT lymphoma is curative in many patients. Watchful waiting 
is appropriate in most patients with asymptomatic advanced stage disease, which tends to 
behave in a particularly indolent manner. Other options for symptomatic disease include 
splenectomy, chemoimmunotherapy with rituximab and, more recently, targeted therapies.  
 
Keywords: mantle-cell lymphoma, marginal zone B-cell lymphoma, disease management, 
rituximab, bendamustine   
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